Clinical data with the anti-VEGF monoclonal antibody, bevacizumab, plus first-line chemotherapy improved efficacy in patients with advanced NSCLC (Sandler et al, 2006; Manegold et al, 2007, 2008), indicating that targeting angiogenesis through VEGF is a viable strategy. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.